TY - JOUR
T1 - Ligand-Directed Acid-Sensitive Amidophosphate 5‑Trifluoromethyl-2′-Deoxyuridine Conjugate as a Potential Theranostic Agent
AU - Godovikova, T.S.
AU - Kaptein, R.
AU - Silnikov, V.N.
AU - et al., [No Value]
PY - 2013
Y1 - 2013
N2 - Herein, we report a novel strategy to engineer
an acid-sensitive anticancer theranostic agent using a vector−
drug ensemble. The ensemble was synthesized by directly
conjugating the linoleic acid (LA)-modified branched polyethyleneimine
with a chemotherapeutic drug trifluorothymidine.
Linoleic acid residues were grafted onto 25 kDa
polyethyleneimine (PEI) by treating PEI with linoleic acid
chloroanhydride. 5-Trifluoromethyl-2′-deoxyuridine (trifluorothymidine,
TFT) was introduced into LA-PEI conjugate by
phosphorylating the conjugate with amidophosphate of
trifluorothymidine 5′-monophosphate (pTFT), which had
been activated by its conversion into the N,N-dimethylaminopyridine
derivative. The extent of mononucleotide analog
incorporation in the polymer was regulated by the ratio of pTFT to the polymer during the synthesis. Samples containing 20−70
TFT residues per PEI molecule were obtained. The cytotoxicity of PEI-LA-pTFT conjugates decreased with increasing
nucleotide content, as examined using the MTT method. Due to the presence of fluorine atoms, TFT-based conjugates could be
detected directly in the animals by 19F magnetic resonance imaging. In addition, the presence of the amidophosphate group in
PEI-LA-pTFT conjugates allowed their detection by in vivo 31P NMR spectroscopy. Indeed, the 31P NMR signal of a
phosphoramide (δ ∼ 12 ppm) was observed in the mouse muscle tissue treated with PEI-LA-pTFT conjugate along with the
signals from endogenous phosphorus-containing compounds. At the same time, the use of PEI-LA-pTFT conjugate for
chemotherapeutic drug delivery is limited due to the low release of pTFT from the carrier. To enhance the release of the drug
from the conjugate in the endosomes, PEI-LA polymer was coupled with urocanic acid (UA), which bears imidazole ring and
thus can form an acid-labile P−N bond with pTFT. The PEI-LA-UA-pTFT conjugate containing 30 residues of UA and 40
residues of pTFT was tested against the murine Krebs-II ascites carcinoma, grown as an ascetic tumor. The intraperitoneal
injection of the conjugates resulted in prolongation of the animals’ life and to the complete disappearance of the tumor after
three injections.
AB - Herein, we report a novel strategy to engineer
an acid-sensitive anticancer theranostic agent using a vector−
drug ensemble. The ensemble was synthesized by directly
conjugating the linoleic acid (LA)-modified branched polyethyleneimine
with a chemotherapeutic drug trifluorothymidine.
Linoleic acid residues were grafted onto 25 kDa
polyethyleneimine (PEI) by treating PEI with linoleic acid
chloroanhydride. 5-Trifluoromethyl-2′-deoxyuridine (trifluorothymidine,
TFT) was introduced into LA-PEI conjugate by
phosphorylating the conjugate with amidophosphate of
trifluorothymidine 5′-monophosphate (pTFT), which had
been activated by its conversion into the N,N-dimethylaminopyridine
derivative. The extent of mononucleotide analog
incorporation in the polymer was regulated by the ratio of pTFT to the polymer during the synthesis. Samples containing 20−70
TFT residues per PEI molecule were obtained. The cytotoxicity of PEI-LA-pTFT conjugates decreased with increasing
nucleotide content, as examined using the MTT method. Due to the presence of fluorine atoms, TFT-based conjugates could be
detected directly in the animals by 19F magnetic resonance imaging. In addition, the presence of the amidophosphate group in
PEI-LA-pTFT conjugates allowed their detection by in vivo 31P NMR spectroscopy. Indeed, the 31P NMR signal of a
phosphoramide (δ ∼ 12 ppm) was observed in the mouse muscle tissue treated with PEI-LA-pTFT conjugate along with the
signals from endogenous phosphorus-containing compounds. At the same time, the use of PEI-LA-pTFT conjugate for
chemotherapeutic drug delivery is limited due to the low release of pTFT from the carrier. To enhance the release of the drug
from the conjugate in the endosomes, PEI-LA polymer was coupled with urocanic acid (UA), which bears imidazole ring and
thus can form an acid-labile P−N bond with pTFT. The PEI-LA-UA-pTFT conjugate containing 30 residues of UA and 40
residues of pTFT was tested against the murine Krebs-II ascites carcinoma, grown as an ascetic tumor. The intraperitoneal
injection of the conjugates resulted in prolongation of the animals’ life and to the complete disappearance of the tumor after
three injections.
U2 - 10.1021/bc3006072
DO - 10.1021/bc3006072
M3 - Article
SN - 1043-1802
VL - 24
SP - 780
EP - 795
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
ER -